World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 5.922

ICV : 78.6

Abstract

MANAGEMENT OF CHEMOTHERAPY TOXICITIES INCLUDING ABVD OR BEACOPP ESCALATED IN THE TREATMENT OF HODGKIN LYMPHOMA

MESSOUNA Mohamed*, MOSSE Wilfred, NDA Guy, LKHOYALI Siham, ICHOU Mohamed and ERRIHANI Hassan

ABSTRACT

Hodgkin lymphoma is cancer mainly affecting B lymphocytes.[1] In Morocco, it accounts for 1.6% of cases recorded during the period 2008 to 2012.[2] The cure rate has increased significantly in recent decades due to a combination of chemotherapy and radiation therapy.[1,3, 3] It is estimated that more than 80% of cases are curable[curable.[1,3,4,3,4] This increase in survival rates is the result of more effective treatments. However, their toxicities remain significant. In our study, we found 49% neutropenia, 26% anaemia, 26% thrombopenia, 35% nausea and vomiting, 32% diarrhea, 9.4% mucite, 39% peripheral neuropathy, 36% alopecia, 29% skin colour, 49.2% pain, 20.2% asthenia and anorexia, 32% diarrhea. There were more neutropenia and peripheral neuropathy in patients treated with BEACOPP ESCALADE, 53.8% vs. 46.8% and 50% vs. 32%, respectively. On the other hand, we found more digestive toxicities (nausea and vomiting, diarrhea) in patients treated with ABVD, respectively 38.5% versus 29% and 37.5% versus 23%).[3,4,5] Grade I and II toxicities did not require discontinuation of treatment or postponement of chemotherapy and were treated as an outpatient, while grades III and IV were hospitalized with clinical and para-clinical examinations.

[Full Text Article]

Powered By WJPMR | All Right Reserved

WJPMR